T

Telomir Pharmaceuticals Inc
NASDAQ:TELO

Watchlist Manager
Telomir Pharmaceuticals Inc
NASDAQ:TELO
Watchlist
Price: 4.27 USD -0.7%
Market Cap: 126.4m USD
Have any thoughts about
Telomir Pharmaceuticals Inc?
Write Note

EV/EBIT
Enterprise Value to EBIT

-6.4
Current
-8.4
Median
16.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-6.4
=
Enterprise Value
126.5m USD
/
EBIT
-19.8m USD
All Countries
Close
EBIT Growth EV/EBIT to Growth
US
T
Telomir Pharmaceuticals Inc
NASDAQ:TELO
Average EV/EBIT: 2 011.5
Negative Multiple: -6.4
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54
45%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
23.4
22%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.7
9%
1.6
US
Merck & Co Inc
NYSE:MRK
12.6
98%
0.1
CH
Roche Holding AG
SIX:ROG
12.4
9%
1.4
UK
AstraZeneca PLC
LSE:AZN
254.5
32%
8
CH
Novartis AG
SIX:NOVN
13.4
17%
0.8
US
Pfizer Inc
NYSE:PFE
16
19%
0.8

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
N/A
2-Years Forward
EV/EBIT
17.7
3-Years Forward
EV/EBIT
21.8